Patents by Inventor David J. Enscore
David J. Enscore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140294920Abstract: A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed.Type: ApplicationFiled: May 16, 2014Publication date: October 2, 2014Inventor: David J. Enscore
-
Publication number: 20040220081Abstract: Bioactive agents may be reproducibly converted into particles having diameters in the range of about 5 to about 2000 nanometers (nm). Conversion is accomplished by dissolving the bioactive agent in a solvent for the bioactive agent, and rapidly altering the polarity of the solution to make it a non-solvent for the bioactive agent, for example by diluting the bioactive agent solution with an excess of a liquid that is a non-solvent for the bioactive agent but is miscible with the solvent. Precipitated bioactive agent nanoparticles are collected by centrifugation, filtration or lyophilization. The nanoparticles have a relatively narrow size distribution, and the average diameter can be controlled by choice of solvent and non-solvent. The nanoparticles are typically amorphous. A surfactant may be added to ensure dispersion of the particles when administered. In the preferred embodiment, the bioactive agent is a drug with low aqueous solubility.Type: ApplicationFiled: October 30, 2003Publication date: November 4, 2004Applicant: Spherics, Inc.Inventors: Mark R. Kreitz, Yong S. Jong, Edith Mathiowitz, David J. Enscore, Michael J. Bassett
-
Patent number: 6350463Abstract: Premature Rupture of the Membranes (PROM) is a serious complication of pregnancy. PROM is treated by creation of a seal or barrier at the site of the rupture or in or near the cervix, thereby controlling the loss of amniotic fluid and preventing bacterial access. Instruments and techniques for application of sealing and barrier-forming materials at appropriate sites are described, as well as appropriate selection of materials and formation techniques. The instruments and techniques facilitate application of any fluent material to physiology associated with pregnancy and rendering the fluent material non fluent so as to form a barrier of seal.Type: GrantFiled: May 21, 1999Date of Patent: February 26, 2002Assignee: Andre BieniarzInventors: Stephen J. Herman, Glenn M. Kazo, David J. Enscore, J. Jeffrey Kablik
-
Patent number: 6177095Abstract: Water-soluble macromers including at least one hydrolysable linkage formed from carbonate or dioxanone groups, at least one water-soluble polymeric block, and at least one polymerizable group, and methods of preparation and use thereof are described. The macromers are preferably polymerized using free radical initiators under the influence of long wavelength ultraviolet light or visible light excitation. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. The macromers can be used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents in a controlled manner, plug leaks in tissue, prevent adhesion formation after surgical procedures, temporarily protect or separate tissue surfaces, and adhere or seal tissues together.Type: GrantFiled: January 7, 2000Date of Patent: January 23, 2001Assignee: Focal, IncInventors: Amarpreet S. Sawhney, Peter K. Jarrett, Arthur J. Coury, Ronald S. Rudowsky, Michelle D. Powell, Luis Z. Avila, David J. Enscore, Stephen D. Goodrich, William C. Nason, Fei Yao, Douglas Weaver, Shikha P. Barman
-
Patent number: 6174545Abstract: An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.Type: GrantFiled: February 3, 1999Date of Patent: January 16, 2001Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, Diane Nedberge, Richard D. Frame
-
Patent number: 6165497Abstract: Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation, preferably at a thermodynamic activity no greater than 0.50, and the reservoir comprises the nicotine dissolved in a polymer with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of nicotine in the reservoir is sufficient to prevent the activity of the nicotine in the reservoir from decreasing by more than about 75% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferably at least 75% initial equilibrated nicotine loading is in the reservoir layer.Type: GrantFiled: March 1, 1991Date of Patent: December 26, 2000Assignee: ALZA CorporationInventors: James L. Osborne, Melinda Nelson, David J. Enscore, Su Il Yum, Robert M. Gale
-
Patent number: 6083524Abstract: Water-soluble macromers including at least one hydrolysable linkage formed from carbonate or dioxanone groups, at least one water-soluble polymeric block, and at least one polymerizable group, and methods of preparation and use thereof are described. The macromers are preferably polymerized using free radical initiators under the influence of long wavelength ultraviolet light or visible light excitation. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. The macromers can be used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents in a controlled manner, plug leaks in tissue, prevent adhesion formation after surgical procedures, temporarily protect or separate tissue surfaces, and adhere or seal tissues together.Type: GrantFiled: October 6, 1997Date of Patent: July 4, 2000Assignee: Focal, Inc.Inventors: Amarpreet S. Sawhney, David J. Enscore, Stephen D. Goodrich, William C. Nason, Fei Yao, Douglas Weaver, Peter K. Jarrett, Arthur J. Coury, Ronald S. Rudowsky, Michelle D. Powell, Luis Z. Avila, Shikha P. Barman
-
Patent number: 6007837Abstract: An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.Type: GrantFiled: February 3, 1999Date of Patent: December 28, 1999Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, Diane Nedberge, Richard D. Frame
-
Patent number: 5783205Abstract: The present invention is directed to a material which can be used to deliver a drug, such as an antibiotic, into a diseased tissue pocket, such as a periodontal pocket. The material is preferably a bioerodible oligomer or polymer. The oligomer or polymer containing the drug is heated and is then delivered, preferably by injection, into the tissue pocket at a physiologically compatible elevated temperature. Once the bioerodible material is injected into the pocket, the material cools to the body temperature of the pocket. As it cools, the material hardens and remains in place in the tissue pocket. The hardened material bioerodes in the pocket and releases the drug over a period of several days.Type: GrantFiled: April 10, 1997Date of Patent: July 21, 1998Assignee: ALZA CorporationInventors: Randall G. Berggren, David J. Enscore, Susan M. Marks, James L. Osborne, Patrick S.-L. Wong, Wouter E. Roorda
-
Patent number: 5633008Abstract: A method of administering nicotine transdermally in which a nicotine patch, capable of administering nicotine for at least 16 hours at rates that are efficacious in smoking cessation therapy, is applied in the morning upon waking and removed prior to sleep. This method is effective even though nicotine is not essential during sleep and many smokers experience morning craving.Type: GrantFiled: August 12, 1993Date of Patent: May 27, 1997Inventors: James L. Osborne, Melinda K. Nelson, David J. Enscore, Su I. Yum, Robert M. Gale, Donna D. Causey
-
Patent number: 5620700Abstract: The present invention is directed to a material which can be used to deliver a drug, such as an antibiotic, into a diseased tissue pocket, such as a periodontal pocket. The material is preferably a bioerodible oligomer or polymer. The oligomer or polymer containing the drug is heated and is then delivered, preferably by injection, into the tissue pocket at a physiologically compatible elevated temperature. Once the bioerodible material is injected into the pocket, the material cools to the body temperature of the pocket. As it cools, the material hardens and remains in place in the tissue pocket. The hardened material bioerodes in the pocket and releases the drug over a period of several days.Type: GrantFiled: May 9, 1995Date of Patent: April 15, 1997Assignee: ALZA CorporationInventors: Randall G. Berggren, David J. Enscore, Susan M. Marks, James L. Osborne, Patrick S.-L. Wong, Wouter E. Roorda
-
Patent number: 5462745Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration: and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: August 30, 1994Date of Patent: October 31, 1995Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5364630Abstract: Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation, preferably at a thermodynamic activity no greater than 0.50, and the reservoir comprises the nicotine dissolved in a material with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of nicotine in the reservoir is sufficient to prevent the activity of the nicotine in the reservoir from decreasing by more than about 75% and preferably no more than about 25% during the predetermined period of administration; and the thickness of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferably at least 75% of the initial equilibrated nicotine loading is in the reservoir layer.Type: GrantFiled: June 21, 1993Date of Patent: November 15, 1994Assignee: Alza CorporationInventors: James L. Osborne, Melinda Nelson, David J. Enscore, Su I. Yum, Robert M. Gale
-
Patent number: 5344656Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: June 16, 1993Date of Patent: September 6, 1994Assignee: ALZA CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5342623Abstract: Rate controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent or a plasticizer for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation, and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and preferably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: June 18, 1993Date of Patent: August 30, 1994Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 5004610Abstract: Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation, preferably at a thermodynamic activity no greater than 0.50, and the reservoir comprises the nicotine dissolved in a material with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of nicotine in the reservoir is sufficient to prevent the activity of the nicotine in the reservoir from decreasing by more than about 75% and preferably no more than about 25% during the predetermined period of administration; and the thickness of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferably at least 75% of the initial equilibrated nicotine loading is in the reservoir layer.Type: GrantFiled: June 14, 1990Date of Patent: April 2, 1991Assignee: ALZA CorporationInventors: James L. Osborne, Melinda Nelson, David J. Enscore, Su I. Yum, Robert M. Gale
-
Patent number: 4938759Abstract: A transdermal delivery device having a release-rate controlling-adhesive is disclosed having improved delivery characteristics. The device employs a polyisobutylene/mineral oil adhesive formulation and an ethylene/viny acetate (EVA) drug reservoir formulation. The device is useful in delivering a wide variety of transdermally administrable drugs, particularly those which are moderately soluble in mineral oil. Preferred embodiments deliver timolol base and atropine base from an EVA (40% VA) reservoir formulation.Type: GrantFiled: September 2, 1986Date of Patent: July 3, 1990Assignee: Alza CorporationInventors: David J. Enscore, Eun S. Lee, Su I. Yum
-
Patent number: 4908027Abstract: Rate-controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferrably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferrably at least 75% initial equilibrated agent loading is in the reservoir layer.Type: GrantFiled: September 12, 1986Date of Patent: March 13, 1990Assignee: ALZA CorporationInventors: David J. Enscore, Patricia S. Campbell, James L. Osborne, Melinda K. Smart, Su I. Yum
-
Patent number: 4904475Abstract: A transdermal delivery device for delivering drugs, typically ionized drugs, from an aqueous reservoir is described. The device comprises an aqueous drug reservoir in the form of a gel confined between an impermeable backing member and a porous support structure. In preferred embodiments the support structure is the substrate to which is applied a porous or patterned in-line adhesive. A strippable release liner is preferably provided on the adhesive while in the package. The devices are usable to deliver drugs such as chlorpheniramine maelate, brompheneiramine maleate and scopolamine hydrobromide.Type: GrantFiled: February 24, 1987Date of Patent: February 27, 1990Assignee: ALZA CorporationInventors: Robert M. Gale, David J. Enscore
-
Patent number: RE39713Abstract: Water-soluble macromers including at least one hydrolysable linkage formed from carbonate or dioxanone groups, at least one water-soluble polymeric block, and at least one polymerizable group, and methods of preparation and use thereof are described. The macromers are preferably polymerized using free radical initiators under the influence of long wavelength ultraviolet light or visible light excitation. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. The macromers can be used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents in a controlled manner, plug leaks in tissue, prevent adhesion formation after surgical procedures, temporarily protect or separate tissue surfaces, and adhere or seal tissues together.Type: GrantFiled: January 23, 2003Date of Patent: July 3, 2007Assignee: Genzyme CorporationInventors: Amarpreet S. Sawhney, Peter K. Jarrett, Arthur J. Coury, Ronald S. Rudowsky, Michelle D. Lyman, Luis Z. Avila, David J. Enscore, Stephen D. Goodrich, William C. Nason, Fei Yao, Douglas Weaver, Shikha P. Barman